Plexium Inc. and AbbVie Inc. entered into an exclusive strategic collaboration to develop and commercialize novel Targeted Protein Degradation (TPD) therapeutics for neurological conditions.
The most obvious risks from COVID-19 are hospitalization and death. But study after study shows the disease comes with an increased risk of a number of health problems, including diabetes.
The U.S. Food and Drug Administration approved Azurity Pharmaceuticals Inc.’s Fleqsuvy (baclofen oral suspension), 25 mg per 5 mL (5 mg/mL), Concentrated Formulation for the treatment of spasticity from multiple sclerosis or patients with spinal cord injuries and other spinal cord diseases.
Neurocrine Bioscience and Acadia Pharmaceuticals posted positive top-line results from their respective Phase III trials on major neurological diseases.
Johnson & Johnson will launch the newly approved drug Ponvory for adults with relapsing multiple sclerosis (MS) in the United States during early April 2021 at a similar price point to rival treatments, the company’s Janssen Pharmaceutical unit said on March 19.
California-based GW Pharmaceuticals initiated the company’s first U.S. Phase III trial studying nabiximols, which is known as Sativex outside the United States, as a potential treatment for multiple sclerosis-associated spasticity.
Federal authorities charged 10 former National Football League players for allegedly defrauding a healthcare program of more than $3.4 million by filing false claims for expensive medical equipment.
Allergan’s Botox was given the green light from the U.S. FDA to treat pediatric patients with lower limb spasticity.